Vutrisiran Efficacy by Baseline ATTR-CM Severity | JACC | ACC.25

5 Views

  • Thanks! Share it with your friends!

    You disliked this video. Thanks for the feedback!

admin
Published
Watch JACC Associate Editor Michelle Kittleson, MD, FACC, and author Mathew S. Maurer, MD, FACC, as they discuss Dr. Maurer’s study published in JACC and presented at ACC.25. This exploratory analysis of HELIOS-B assessed the efficacy of vutrisiran versus placebo in patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM) by subgroups of baseline heart failure severity (primarily by NYHA class and NT-proBNP levels). Vutrisiran showed evidence of benefit vs placebo on mortality, cardiovascular events, functional capacity, quality of life, and cardiac biomarkers across the range of baseline disease severities in patients enrolled in HELIOS-B, with greatest benefit observed in patients with earlier, less severe disease. #jacc #jaccjournals #acc25
Category
Cardiology
Be the first to comment

Up Next